Abstract
Clinical observation suggested a high prevalence of cardiac morbidity and mortality in children with Ewing sarcoma (ES) treated at B.C.'s Children's Hospital. We therefore compared 30 patients treated for Ewing sarcoma between 1978 and 1991 with 26 soft tissue sarcoma (STS) patients treated with similar chemotherapy over the same period of time. All patients were evaluated for cardiac function using echocardiography. Shortening fraction (SF) and left ventricular mass index (Massl) were compared before and after treatment. The role of chest irradiation, dose concentration (DC) of adriamycin (AD), total mean doses of AD, cyclophosphamide (CY) and actinomycin (AC) were analysed. SF for patients with ES and STS postchemotherapy was significantly lower (P < .001 and P = 0.0004, respectively) than pretreatment values. Postchemotherapy SF for ES was lower than STS (P = 0.0097). Massl for each group did not change significantly. Six of the ES patients had postchemotherapy SF of < 0.20, with three in congestive failure, two cardiac deaths and one heart transplant. One additional ES patient had sick sinus syndrome and needed a pacemaker. Among the STS patients only one had SF < .20 and none were symptomatic. There were no significant dif...Continue Reading
References
Jun 1, 1979·Cancer·B A Mills, R W Roberts
Nov 1, 1979·Annals of Internal Medicine·D D Von HoffF M Muggia
Dec 1, 1978·Circulation·D J SahnA Weyman
Apr 1, 1977·Cancer·R A MinowJ A Gottlieb
Feb 1, 1976·Cancer·A C GilladogaM L Murphy
Mar 1, 1991·American Journal of Hematology·R G Watts
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Nov 11, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoR C Young
Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Sep 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E O BurgertP Thomas
Dec 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W M Hryniuk, M Goodyear
Aug 1, 1973·Cancer·E A LefrakJ A Gottlieb
Feb 1, 1974·Annals of Internal Medicine·R H Blum, S K Carter
May 1, 1983·Southern Medical Journal·M ObamaJ van Eys
Jun 15, 1981·Cancer·A M GoorinN Jaffe
Jan 1, 1981·Medical and Pediatric Oncology·L J SteinherzD R Miller
Jul 1, 1980·The Journal of Pediatrics·T BiancanielloS Kaplan
Jun 1, 1995·Medical and Pediatric Oncology·L J SteinherzC Tan
Mar 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W CristR Heyn
Aug 4, 1994·The New England Journal of Medicine·O DelattreT J Triche
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S L HancockR T Hoppe
Jan 1, 1993·Medical and Pediatric Oncology·J H SilberG Barber
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R I JakackiJ H Silber
Citations
Oct 16, 1999·British Journal of Haematology·G Levitt
Jul 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L C M KremerP A Voûte
Feb 27, 2004·British Journal of Haematology·G A LevittI Sullivan
Feb 6, 2013·Pediatric Blood & Cancer·Tanya Renae BrownChristopher Fryer
Oct 16, 2009·Pediatric Blood & Cancer·Mathias RatheGunner Nielsen
Jan 16, 1999·Pediatric Clinics of North America·M Grossi
Oct 12, 2001·Clinical Cardiology·D IarussiA Iacono
Dec 8, 2005·Pediatric Blood & Cancer·M PaulidesUNKNOWN German Late Effects Working Group in the Society of Pediatric Oncology and Haematology (GPOH)
May 6, 2005·Paediatric Drugs·Diana IarussiRaffaele Calabrò
Dec 10, 2008·Pediatric Hematology and Oncology·Mehmet KantarSavas Kansoy
Oct 3, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L HensleyD G Pfister